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Abstract
Rationale Second-generation antipsychotics occupy dopa-
mine D2 receptors and act as antagonists or partial agonists
at these receptors. While these drugs alleviate positive symp-
toms in patients with schizophrenia, they are less effective for
treating cognitive deficits and negative symptoms. Dopamine
D3 receptors are highly expressed in areas of the brain thought
to play a role in the regulation of motivation and reward-
related behavior. Consequently, the dopamine D3 receptor
has become a target for treating negative symptoms in
combination with D2 antagonism to treat positive symptoms
in patients with schizophrenia.
Objective The purpose of this study was to determine the
cariprazine receptor occupancies in brain for D2 and D3 recep-
tors in patients with schizophrenia.
Methods Using [11C]-(+)-PHNO as a radioligand, positron
emission tomography (PET) scans were performed in eight
patients at baseline and postdose on days 1, 4, and 15.
Plasma and cerebrospinal fluid (CSF) samples were analyzed
for cariprazine concentrations.
Results A monotonic dose-occupancy relationship was ob-
served for both receptor types. After 2 weeks of treatment,
near complete (∼100 %) occupancies were observed for both
receptors at a dose of 12 mg/day. At the lowest cariprazine
dose (1 mg/day), mean D3 and D2 receptor occupancies were
76 and 45 %, respectively, suggesting selectivity for D3 over
D2 receptors at low doses. An exposure-response analysis
found a ∼3-fold difference in EC50 (D3 = 3.84 nM and
D2 = 13.03 nM) in plasma after 2 weeks of dosing.
Conclusion This PET imaging study in patients with schizo-
phrenia demonstrated that cariprazine is a D3-preferring dual
D3/D2 receptor partial agonist.
Keywords Antipsychotic . [11C]-(+)-PHNO . Cariprazine .
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Introduction
Cariprazine (RGH-188) is an orally active, high-affinity do-
pamine D3 and D2 receptor partial agonist with preferential
binding to D3 receptors (Kiss et al. 2010). A D3 strategy for
Electronic supplementary material The online version of this article
(doi:10.1007/s00213-016-4382-y) contains supplementary material,
which is available to authorized users.
* Ragy R. Girgis
ragygir@nyspi.columbia.edu
1 Department of Psychiatry, New York State Psychiatric Institute,
Columbia University, 1051 Riverside Drive Unit 31, New
York, NY 10032, USA
2 New York State Psychiatric Institute (NYSPI), Columbia University
Medical Center, New York, NY, USA
3 Clinical Neuroscience Research Unit (CNRU), Yale School of
Medicine, New Haven, CT, USA
4 Department of Psychiatry, Yale University School of Medicine,
Yale PET Center, New Haven, CT, USA
5 Forest Research Institute, Jersey City, NJ, USA
6 Present address: Pharmaceutical Product Development, LLC,
Richmond, VA 23230, USA
7 Inncelerex, Jersey City, NJ, USA
8 Gedeon Richter Plc., Budapest, Hungary
Psychopharmacology (2016) 233:3503–3512
DOI 10.1007/s00213-016-4382-y
treatment of schizophrenia is based on the brain distribution
and putative role of D3 receptors (Gross and Drescher 2012);
these receptors have high density in the ventral striatum
(Gurevich and Joyce 1999), one of the core areas in the pa-
thology of schizophrenia, as well as depression and anxiety. In
preclinical models, dopamine D3 receptor antagonists re-
versed cognitive impairment (Laszy et al. 2005; Millan et al.
2007; Sigala et al. 1997) and enhanced locomotor activity of
habituated rats (Gyertyán and Sághy 2004; Sautel et al. 1995;
Waters et al. 1993), suggesting potential for improving nega-
tive symptoms. However, highly selective D3 receptor antag-
onists failed to show antipsychotic efficacy in preclinical
models of schizophrenia (Millan et al. 2000; Reavill et al.
2000) suggesting that D3 receptor antagonism alone is not
sufficient for antipsychotic efficacy.
It has been shown that ∼60–80 % occupancy of dopamine
D2 receptors is necessary to achieve antipsychotic action in the
clinic (Nyberg et al. 1996; Seeman 2001). It has therefore been
hypothesized that combined occupancy of dopamine D3 and
D2 receptors may offer distinct advantages over existing anti-
psychotics with primarily D2 receptor antagonism in the treat-
ment of schizophrenia (Gyertyán et al. 2008; Kiss et al. 2008).
In rodent models, cariprazine pretreatment significantly di-
minished scopolamine- and PCP-induced cognitive deficits
(Zimnisky et al. 2013) and stress-induced anhedonia
(Gyertyán and Sághy 2004; Sautel et al. 1995; Waters et al.
1994); in knockout mice, these effects were found to be D3-
receptor dependent (Zimnisky et al. 2013). Cariprazine has
also shown clinical potential for treating negative symptoms
based on results from a post hoc analysis of a phase II study in
patients with schizophrenia (Debelle et al. 2014) as well as
recent results from a prospectively defined schizophrenia
study of patients with persistent and predominant negative
symptoms (Debelle et al. 2015). One study found negative
results of D3 receptor antagonists in schizophrenia (Redden
et al. 2011); however, this study may have been limited by low
occupancies at the tested doses (Graff-Guerrero et al. 2010).
Previous in vivo imaging studies exploring the binding
profile of cariprazine in humans and nonhuman primates char-
acterized the D2 receptor binding profile of cariprazine but
were not informative about its D3 receptor-binding profile
( S e n e c a e t a l . 2 0 11 ) . [ 1 1C ] - ( + ) - 4 - p r o p y l - 9 -
hydroxynaphthoxazine ([11C]-(+)-PHNO) is a recently devel-
oped D3/D2 agonist positron emission tomography (PET)
radioligand with preferential in vivo selectivity for dopamine
D3 over D2 receptors (Gallezot et al. 2012; Ginovart et al.
2007; Graff-Guerrero et al. 2009; Willeit et al. 2006; Wilson
et al. 2005). In contrast to previously used tracers like
[11C]raclopride, [11C]-(+)-PHNO binding is due mostly to
D3 receptors in the substantia nigra and ventral tegmental area,
D2 receptors in the dorsal striatum, and a mixture of both types
in globus pallidus, ventral striatum, and thalamus. This mixed
binding profile can be exploited to infer the occupancy by
antipsychotic drugs at D2 and D3 receptors separately
(Girgis et al. 2011; Rabiner et al. 2009; Searle et al. 2010).
The pharmacokinetic (PK) properties of cariprazine in
humans are characterized by relatively slow absorption,
multi-exponential disposition, and slow elimination with a
long terminal elimination half-life (T½). Two major active
metabolites, desmethyl cariprazine (DCAR) and di-
desmethyl cariprazine (DDCAR), were identified and moni-
tored in clinical studies (Kapás et al. 2008; Mészáros et al.
2007). At steady state, DDCAR is the predominant active
moiety, with systemic exposure that is about 2- to 3-fold
higher than cariprazine; DCAR systemic exposure is around
30–40 % of parent drug exposure (Nakamura et al. 2016).
DCAR and DDCAR have exhibited partial agonist activity
at both D2 and D3 receptors and have displayed 21- and 25-
fold selectivity, respectively, for cloned human D3 versus D2L
receptors (unpublished data) compared with a 6- to 8-fold D3
selectivity for the parent compound (Kiss et al. 2010).
Moreover, DDCAR also showed somewhat lower intrinsic
activity at cloned human D2 receptors compared with
cariprazine (Tadori et al. 2011). The activity of cariprazine
after multiple dosing is, therefore, expected to be attributable
to the parent drug and its two active metabolites.
This study was designed to assess the binding and occu-
pancy of cariprazine, DCAR, and DDCAR to D3 and D2 re-
ceptors in various regions of the brain in adult patients with
schizophrenia using PET imaging with [11C]-(+)-PHNO and
to assess the relationship between occupancy and plasma con-
centrations of cariprazine and its two active metabolites.
Materials and methods
Clinical study design
This was an open-label, multiple-dose study in patients (ages
18–55 years, inclusive) with a primary diagnosis of schizo-
phrenia according to Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-
TR) (APA 2000) criteria based on the Structured Clinical
Interview for the DSM-IV (First et al. 2007). There were three
different dosing cohorts with three patients each (Fig. S1); all
had initial up-titration to the final dose to improve tolerability.
Cohort 1 received 1.5 mg on day 1, 3 mg on day 2, 6 mg once
daily (QD) on days 3–4, 9 mgQD on days 5–6, and 12mgQD
on days 7–15. Cohort 2 received 0.5 mg on day 1, 1 mgQD on
days 2–4, and 3 mg QD on days 5–15. Cohort 3 received
0.5 mg QD on days 1–4 and 1 mg QD on days 5–15. The
study was conducted at the New York State Psychiatric
Institute (NYSPI) at Columbia University Medical Center
and the Clinical Neuroscience Research Unit (CNRU)/
Schizophrenia Research Clinic at Yale University. All PET
scans and pharmacokinetic and cerebrospinal fluid (CSF)
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sample collections were performed at Yale University. PET
data analysis was done at Columbia University. The study
protocol was approved by the Yale and NYSPI Institutional
Review Boards and was conducted in compliance with the
ICH Good Clinical Practice guidelines and the Declaration
of Helsinki. Patients provided signed informed consent at
screening and had the capacity to understand it. Participants
were compensated for their participation.
Dynamic PET scans were acquired with [11C]-(+)-PHNO.
A maximum of five PET scans were performed for each pa-
tient to evaluate D3 and D2 receptor occupancy on day 1 at
predose (baseline) and 4 h postdose (after plasma PK sam-
pling), on day 4 at 4 h postdose (after plasma PK sampling),
on day 15 at 4 h postdose (after plasma PK sampling), and on
day 24 after the plasma PK sampling. The average injected
radioactivity was 564 ± 157 MBq, specific activity was
80 ± 33 MBq/nmol, and injected mass was 2.0 ± 0.48 μg.
Safety was assessed by adverse event (AE) recording, clin-
ical laboratory tests, vital sign assessments, electrocardiogra-
phy, physical and psychiatric examinations, and Columbia–
Suicide Severity Rating Scale (C-SSRS) (Posner et al. 2011),
Clinical Global Impressions–Severity scale (CGI-S) (Guy,
1976), and extrapyramidal symptoms scales (Barnes
Akathisia Rating Scale (Barnes 1989), Abnormal
Involuntary Movement Scale (Guy 1976), and Simpson-
Angus Scale (Simpson and Angus 1970)).
Blood sample collection and processing
Blood samples for determining cariprazine, DCAR, and
DDCAR concentrations in plasma were collected using a
prechilled 4-mL Vacutainer tube (containing K2EDTA as an
anticoagulant) on days 1/2, 4/5, and 15/16 at 0 h (predose) and
1, 2, 4, 6, 8, 19, and 24 h post days 1, 4, and 15 dosing and on
day 24 at 216 h after the day-15 dose; plasma was also col-
lected predose on day 3. Blood samples for PK evaluation
were centrifuged within 30 min of drawing at ≥2500g for
10 min at 4 °C and the plasma was harvested. After centrifu-
gation, plasma samples were transferred into prechilled, coded
polypropylene tubes. Samples were flash-frozen in an isopro-
pyl alcohol/dry ice bath and stored at approximately −70 °C.
Additional blood samples were collected for clinical laborato-
ry analysis.
Cerebrospinal fluid collection
CSF samples were collected on day 3 (predose) and day 16
(approximately 24 h after day-15 dose). Lumbar punctures
were performed using standard aseptic technique and a
20-mL Quincke or 25-mL Sprotte needle. A maximum of
10 mL of CSF was collected for PK analyses.
Bioanalytical method
Plasma and CSF concentrations of cariprazine, DCAR, and
DDCAR were measured using a liquid chromatography
coupled with tandem mass spectrometry (LC-MS/MS) meth-
od, validated to demonstrate the accuracy, linearity, reproduc-
ibility, and precision of the analytical procedure. The lower
limit of quantitation (LLOQ) for the plasma assay was
20:20:50 pg/mL for cariprazine/DCAR/DDCAR using a plas-
ma sample volume of 200 μL; the LLOQ for the CSF assay
was 5:5:10 pg/mL, respectively, using a sample volume of
250 μL.
PET and radiochemistry methods
[11C]-(+)-PHNO was prepared by N-acylation of the
despropyl precursor with [11C]-propionyl chloride followed
by reduction of the resulting amide with lithium aluminum
hydride and purification by reverse-phase high-performance
liquid chromatography (HPLC) (Wilson et al. 2005). All scans
were 120 min, following a single bolus injection of [11C]-(+)-
PHNO. Data were acquired on a Siemens High-Resolution
Research Tomograph (HRRT, Siemens/CTI, Knoxville, TN).
Data were acquired in list mode, reconstructed using the
MOLAR algorithm (Carson et al. 2003) including correction
for subject motion using an optical detection system (Vicra,
NDI Systems, Waterloo, Ontario, Canada) and binned into a
sequence of 33 frames of increasing duration (6 × 30 s,
3 × 1 min, 2 × 2 min, 22 × 5 min). AT1-weighted anatomical
magnetic resonance imaging (MRI) scan was acquired for
each subject. Regions of interest (ROIs) were drawn individ-
ually for each subject on their MRI; they included caudate and
putamen, ventral striatum, globus pallidus, thalamus,
substantia nigra/ventral tegmental area, and cerebellum as a
reference tissue. Left and right sides were averaged. PET data
were coregistered to subjects’MRIs; ROIs were applied to the
coregistered PET images. Time activity curves were generated
as the average ROI activity in each frame.
Statistical analysis
Pharmacokinetics
The principal parameters describing the PK of cariprazine,
DCAR, and DDCAR were derived from plasma concentra-
tions using noncompartmental analysis with the validated
software program Phoenix WinNonlin version 6.1
(Pharsight, St. Louis, MO). The plasma PK parameters for
cariprazine and its metabolites were calculated after dosing
on days 1, 4, and 15. Reported parameters included area under
the curve (AUC) over 24 h, peak concentration (Cmax), time of
maximum concentration (Tmax), and trough concentration
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(Cmin). Concentration in CSF (Ccsf) at 24 h after last dose was
also determined.
PET analysis
Reference tissue-based kinetic modeling was performed on all
data using the basis function version of the simplified refer-
ence tissue method (SRTM) (Gunn et al. 1997; Lammertsma
and Hume 1996), with cerebellum as the reference tissue. The
primary outcomemeasure was the binding potential relative to
the nondisplaceable compartment (BPND) (Innis et al. 2007).
The fractional change in BPND across conditions (ΔBPND)
was computed as the relative change between baseline BPND
and BPND during each condition:
ΔBPND ¼ BPND baselineð Þ−BPND postdoseð ÞBPND baselineð Þ
ΔBPND data from each condition were entered into a non-
linear regression model to extract the specific contribution of
D2 and D3 receptors (Girgis et al. 2011; Rabiner et al. 2009;
Searle et al. 2010). In this model, BPND in each region is
parsed into its D2 and D3 components from each scan and
condition. We defined fD3 as the fraction of total BPND attrib-
utable to D3 binding, which in general, varies across regions
but is similar across subjects. Under these assumptions,
ΔBPND following cariprazine is:
ΔBPND ¼ f D3OCCD3 þ 1− f D3ð ÞOCCD2
where OCCD3 and OCCD2 are the occupancies at D3 and D2
receptors by cariprazine and its metabolites. For a given scan,
OCCD3 and OCCD2 are treated as equal across brain regions
(though not across receptor types), but their values vary across
scans. The [11C]-(+)-PHNO BPND data were fitted to this
equation with ΔBPND for each scan and region as input to
the model. Two methods were applied. In method 1, fD3 for
each region was treated as a fixed parameter according to the
values in (Searle et al. 2010), and OCCD3 and OCCD2 were
estimated for each subject and day, obtained as parameter
estimates using ordinary linear least squares fitting. In method
2, in addition to the two occupancy parameters, fD3was treated
as a fitted parameter and all parameters were estimated by
nonlinear least squares fitting. In each region, fD3 was treated
as equal across subjects. These fits were done for each day
leading to 54 or 60 ΔBPND dependent variables (10 subjects
on day 1, 9 for all other days, 6 regions per subject) and 18 or
20 estimated parameters for method 1 (two occupancies for
each subject on that day) or 24 or 26 estimated parameters for
method 2 (six fD3s estimated for the day and two occupancies
for each subject on that day). In theory, fD3 may vary across
subjects but estimating it for each subject might require a
richer data set (e.g., multiple doses within subject under each
condition) to allow reliable estimation. Thus, single values
across subjects, whether fixed or fitted, were considered more
parsimonious, given the available data and the general consis-
tency of fD3 observed across primate species and subjects
(Rabiner et al. 2009; Searle et al. 2010; Slifstein et al. 2012).
Pharmacokinetic-pharmacodynamic PET analysis
The relationships between D3 and D2 receptor occupancy and
plasma levels of cariprazine and its metabolites at the time of
PETwere explored by fitting the plasma concentration of total
active cariprazine (cariprazine + DCAR + DDCAR) versus
occupancy data using an Emax model from the library of phar-
macodynamic (PD) models provided within Phoenix
WinNonlin (version 6.1):
Effect %occupancyð Þ ¼ Emax
 concentration= EC50 þ concentrationð Þ
where EC50 is the expected concentration for 50 % occupancy
and Emax is the maximum occupancy. Emax upper boundswere
set to 100 % for this analysis. Additionally, administered
doses were fitted to a similar equation to obtain ED50, the
expected dose leading to 50 % occupancy according to:
%Occupancy ¼ 100 dose= ED50 þ doseð Þ
Results
Patients
Nine patients (seven men, two women) aged 24 to 55 years
were enrolled. One patient (cohort 1) experienced emesis on
day 4 and withdrew; this subject’s day 1 data were included in
the analysis.
Pharmacokinetics
Plasma concentrations of cariprazine, DCAR, and DDCAR in
cohort 1 are presented in Fig. 1. Total active cariprazine during
the 24-h interval after day-1 dosing consists primarily of par-
ent drug; exposure of the DCAR metabolite slowly increased,
while plasma concentration of the DDCAR metabolite was
below the LLOQ of the bioanalytical assay (Fig. 1a). After
subchronic dosing (15 days), plasma active drug level
consisted primarily of cariprazine and DDCAR, while
DCAR level was substantially lower (AUC ∼25–40 % of par-
ent drug exposure) (Fig. 1b). On day 24, 9 days following the
final dose, plasma levels of cariprazine and DCAR decreased
substantially, while DDCAR level decreased to a smaller ex-
tent (from 21.22 ng/ml at 24 h post day-15 dose to 13.11 ng/
mL on day 24), suggesting a longer half-life (Fig. 1c).
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Because the three cohorts had different periods of dose up-
titration to improve drug tolerability, results are presented sep-
arately by day of treatment (Supplemental Table 1). Plasma
exposure (Cmax, Cmin, and AUC) of all three components, in
general, increased with dose and were consistent with dose
proportional PK by day 15.
In all three cohorts, mean CSF concentrations of DCAR
and DDCAR 24 h after the final dose ranged from 18 to 35
and 94–120 %, respectively, of those of cariprazine
(Supplemental Table 1); corresponding mean plasma trough
(Cmin) concentrations of DCAR and DDCAR (based on nM
concentrations) were 29–53 and 139–203 %, respectively, of
those of cariprazine. On average, concentrations of
cariprazine, DCAR, and DDCAR in CSF were approximately
5–10, 4–6, and 3–8 % of the respective concentrations in
plasma.
PET results
Figure 2 shows ΔBPND by condition and dose for each region.
Under each dosing condition (acute, day 4/5, subchronic),
there was a clear dose response, with the magnitude of
ΔBPND increasing as a function of dose. Both occupancy
models gave similar results for subchronic dosing, but model
2 did not reliably estimate fD3 on days 1 and 4 due to the
similarity of occupancy at both receptor types at these times;
therefore, we report method 1 results only (fD3 fixed to litera-
ture values). Figure 3 depicts the receptor occupancies at D3
and D2 receptors in each cohort and at each time of the PET
measurement. In all three cohorts, receptor occupancies in-
creased from days 1 to 4 to 15 as the doses were increased
with initial slow up-titration, and decreased from days 15 to 24
following cessation of cariprazine administration. Amonoton-
ic dose-occupancy relationship was observed at both receptor
types, with days 4, 15, and 24 following the order occupancy
(cohort 1) > occupancy (cohort 2) > occupancy (cohort 3).
Near-complete (100 %) receptor occupancy at both receptor
types was observed at 12 mg/day on day 15. At the lowest
dose of 1 mg/day, mean D3 and D2 receptor occupancy on day
15 was 76 % (range 58–89 %) and 45 % (range, 14–64 %),
respectively. At the intermediate 3-mg/day dose, mean D3 and
D2 receptor occupancies were 92 % (range, 86–96 %) and
79 % (range, 68–88 %), respectively. Occupancy was reduced
in all brain regions in all three cohorts 9 days after the last dose
of cariprazine, suggesting reversibility of receptor binding.
Mean receptor occupancy decreased from 76 % (range, 58–
89 %) to 20 % (range, −2 to 31 %) for D3 and 45 % (range,
14–64 %) to 32 % (range, 23–48 %) for D2 between days 15
and 24 in cohort 3 after 1 mg of final daily dosing. Similarly, at
the final dose of 3 mg in cohort 2, mean receptor occupancy
decreased from 92 to 54 % for D3 and 79 to 40 % for D2. At
the highest dose of 12 mg, drug exposure resulted in complete
occupancy for both receptor types and did not decrease sub-
stantially even after 9 days of drug washout (D3 from 99 to
97 % and D2 from 95 to 77 %) suggesting that high levels of
active drug were still present 9 days after the 12-mg dose on
day 15.
ED50 estimates and 95 % confidence intervals (CIs) for
acute (day 1/4) and subchronic (day 15) doses were 1.52
(0.76, 3.05) and 0.30 (0.15, 0.59) mg for D3 occupancy and
1.84 (1.41, 2.40) and 1.03 (0.54, 2.05) mg for D2 occupancy
using method 1. One subject taking 12 mg/day had a D3 oc-
cupancy estimate that exceeded 100 %. As a result, the dose-
occupancy relationship for subchronic administrationwas also
Fig. 1 Plasma concentration (mean ± SD) of cariprazine and its
metabolites as a function of time in cohort 1. Cohort 1 received one
1.5 mg tablet on day 1, 3 mg on day 2, 6 mg once daily on days 3–4,
9 mg once daily on days 5–6, and 12 mg once daily on days 7–15. The
concentration versus time profiles for all three active moieties of
cariprazine are shown during the 24-h interval after dose on day 1 (a),
during the 24-h interval after dose on day 15 (b), and interval from days 1
to 24 (with last dose administered on day 15) (c)
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fitted with the D3 occupancy estimate from this subject
constrained to 100 % and with the subject’s data dropped; this
had a negligible effect on the estimated D3 ED50 for
cariprazine, with values of 0.3049 and 0.3064 mg, respective-
ly, compared to 0.3018 mg using the original data. The D3
versus D2 receptor selectivity ratio of cariprazine treatment
was more apparent following subchronic dosing (range,
3.43–5.75) than after an acute dose (range, 1.21–1.31), and
was similar for both methods. Selectivity estimates for D3
compared with D2 overall ranged from about 3- to 6-fold after
subchronic dosing.
Pharmacokinetic-pharmacodynamic analyses
Occupancy at D3 and D2 receptors and plasma concentrations
of total active cariprazine (cariprazine + DCAR + DDCAR) at
the time of the PET scans (4 h postadministration) following
acute (days 1 and 4) and subchronic treatment (day 15) were
fitted to an Emax model (Fig. 4).
The slope for receptor occupancy was quite steep after
acute dosing for both receptors suggesting relatively small
drug concentration necessary to occupy both receptors. The
EC50 (± SE) was similar between the two receptors (D3 = 1.42
[0.37] nM and D2 = 1.77 [0.39] nM) with a ratio of D3/D2 of
about 1.25, consistent with that observed from ED50 analysis.
PK-PD analysis of data collected after subchronic admin-
istration (15-day dosing) allowed more time for equilibration
between plasma and brain regions, as well as accumulation of
slow-forming active metabolite(s), DDCAR in particular. This
demonstrated EC50 (± SE) estimates for D3 and D2 receptor-
rich regions of 3.84 (1.85) and 13.03 (6.8) nM, respectively.
The ratio of EC50 for D3/D2 receptor occupancy of 3.4 sug-
gests preferred affinity at D3 compared to D2 receptors after
multiple-daily dosing of cariprazine for about 2 weeks.
Discussion
The objectives of this study were to assess D3 and D2 receptor
occupancy of cariprazine and its two major active metabolites,
DCAR and DDCAR, in patients with schizophrenia using
[11C]-(+)-PHNO PET imaging, and to explore the relationship
between plasma concentrations of cariprazine/DCAR/
DDCAR and D3 and D2 receptor occupancy.
Cariprazine was well absorbed following oral administra-
tion. Following the first dose, cariprazine was the most prom-
inent moiety in plasma. The mean plasma AUC of cariprazine
on day 1 was 5- to 10-fold higher than the desmethyl metab-
olite DCAR. The di-desmethyl metabolite DDCAR was not
measurable after the first dose on day 1. After 2 weeks of
Fig. 2 The percent decrease in binding potential (ΔBPND) by day and
dose. Error bars are standard deviations. Acute doses were 1.5 mg (n = 3)
and 0.5 mg (n = 6). Day 4/5 doses (day 4, n = 7; day 5, n = 1) were 6 mg
(n = 2), 1 mg (n = 3), and 0.5 mg (n = 3). Subchronic doses (day 15, n = 6;
day 11, n = 1, day 17, n = 1) were 12 mg (n = 2), 3 mg (n = 3), and 1 mg
(n = 3). GP globus pallidus, PUT putamen, CAD caudate nucleus, VST
ventral striatum, THAL thalamus, SN/VTA substantia nigra/ventral
tegmental area
Fig. 3 Occupancy estimates on different days of dosing using fixed literature values for the D3 fraction of regional [
11C]-(+)-PHNO BPND (method 1)
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multiple-dose administration, DDCAR and cariprazine were
the most prominent moieties in plasma; hence, DDCAR may
be responsible for a significant portion of the pharmacological
activity of cariprazine following chronic oral administration.
In vitro plasma protein binding in various species (including
human) is about 96 % (data on file). The concentrations of
cariprazine, DCAR, and DDCAR in CSF in this study were 5–
10, 4–6, and 3–8% of the respective concentrations in plasma.
The CSF/plasma ratio observed in this study was comparable
to the free fraction in plasma (∼4 %), indicating equilibration
of free drug and its active metabolites across the blood-brain
barrier between plasma and CSF compartments.
The observed PET data show that in patients with schizo-
phrenia, cariprazine robustly binds to both D3 and D2 recep-
tors, and is moderately D3-preferring following subchronic
(15-day) dosing with ED50 and EC50 ratios in the three to
six range. These results are consistent with preclinical studies
showing binding to both D3 and D2 receptors in vivo
(Gyertyán et al. 2011) and preferential binding to D3 receptors
in vitro (Kiss et al. 2010) as well as PET studies in nonhuman
primates (Seneca et al. 2011; Toth et al. 2013) and humans
(Keator et al. 2009; Laszlovszky et al. 2007; Potkin et al.
2009) showing that cariprazine binds to D2 receptors.
However, these prior PET studies were performed with
[11C]raclopride and [18F]fallypride, and did not allow for sep-
arate assessment of D3 and D2 receptor binding. In addition,
the maximum cariprazine doses in the two prior human stud-
ies (1.0 and 3.0 mg) were lower than doses investigated in
clinical efficacy studies.
Both ED50 and EC50 demonstrated comparable D3/D2 re-
ceptor selectivity after acute drug administration (days 1 and
4), while 2 weeks of daily dosing showed 3- to 6-fold higher
selectivity (lower EC50 and ED50) for D3 over D2 receptors.
The D3 receptor-preferring nature of cariprazine and its me-
tabolites following subchronic dosing was similar using either
method that was tested (methods 1 or 2). Lower selectivity
following acute dosing may be due in part to rapid changes in
drug and metabolite levels in the body during this transient
period, but additionally, the metabolites of cariprazine are
more D3 receptor preferring than cariprazine itself. In vitro,
DCAR is approximately 2-fold more potent than cariprazine
at human D3 receptors and DDCAR displayed somewhat low-
er affinity (∼2-fold) than cariprazine at human D2 receptors
(Tadori et al. 2011). Considering the contribution of DDCAR
to total active cariprazine was greater after 2 weeks of dosing
than after the initial dose on day 1, the differential affinities of
these moieties may help explain the greater selectivity for D3
receptors after subchronic dosing. The active metabolite,
DDCAR, is formed slowly and takes a few weeks to reach
steady state. In order to improve tolerability in patients with
schizophrenia, clinical studies with longer treatment duration
utilized a dose up-titration during the first week of treatment.
During up-titration, cariprazine levels increased rapidly and
contributed to the immediate pharmacological effect. It took
about 3 weeks to achieve 90 % of steady state for total active
cariprazine concentration and 4 weeks for DDCAR; at steady
state, about 70 % of the total active concentration comprised
the metabolite DDCAR with cariprazine and DCAR contrib-
uting the remaining 20 and 10 %, respectively (Nakamura
et al. 2016). Hence, the complex PK and differential receptor
affinities of cariprazine and its two major metabolites result in
rapid onset of pharmacological effect mostly by the parent
cariprazine during the first week of treatment followed by a
sustained maintenance of anti-D3/D2 activity by the longer
acting metabolite, DDCAR, following chronic dosing. The
D3/D2 binding profiles of the metabolites may also explain
why D3 receptor binding of cariprazine is sustained and in-
creases with subchronic dosing, while currently available an-
tipsychotic agents seem to bind to D3 receptors in expected
proportions after acute dosing (Girgis et al. 2015) but not after
Fig. 4 Receptor occupancy versus total active cariprazine in plasma after
dosing on days 1, 4, and 15 fitted to an Emax model. D3 and D2 receptor
occupancies versus total active cariprazine plasma concentration are
shown after acute treatment (a, b) and subchronic treatment (c, d)
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subchronic dosing (Graff-Guerrero et al. 2009; McCormick
et al. 2010; Mizrahi et al. 2011).
Limitations of this study include the relatively small sam-
ple size, different dosing schedules, and the fact that we could
only measure occupancy for cariprazine and its metabolites
combined without estimating their individual contributions.
However, these limitations do not prevent clear interpretation
of the main results.
In conclusion, this PET imaging study using [11C]-(+)-
PHNO in patients with schizophrenia demonstrated that
cariprazine and/or its metabolites bind robustly to dopamine
D2 and D3 receptors in vivo; this binding is moderately D3
receptor-preferring, with ED50 and EC50 ratios in the 3- to 6-
fold range. All currently available antipsychotic medications
in the USA are more selective for D2 than D3 receptors.
Evidence from animal models suggests that combining potent
D3 with D2 receptor antagonism resulting in high brain occu-
pancy and effective modulation of both receptors may yield
antipsychotic compounds with a better profile for improving
negative symptoms as well as cognitive deficits (Gyertyán
et al. 2008; Kiss et al. 2008). Cariprazine, with its D3-prefer-
ring profile, may provide a new treatment option for patients
with schizophrenia, with a potential for advantages in treating
negative symptoms and cognitive impairment.
Acknowledgments Editorial support for manuscript preparation was
provided by Paul Ferguson, M.S., of Prescott Medical Communications
Group, Chicago, Illinois, a contractor of Forest Research Institute, an
Allergan affiliate. The clinical study was monitored by Dahlia Henry of
Forest Research Institute, an Allergan affiliate. The authors would like to
acknowledge the nursing staff of the Clinical Neuroscience Research
Unit, the Schizophrenia Neuropharmacology Research Group at Yale
(SNRGY), and the Yale PET Center for their critical contributions to-
wards the success of this study. All experiments in this study comply with
the current laws of the country in which they were performed.
Compliance with ethical standards
Conflict of interest Support for this research and publication was
funded by Forest Laboratories, LLC, Jersey City, New Jersey, USA, an
Allergan affiliate, and Gedeon Richter, Plc, Budapest, Hungary. Forest
Laboratories and Gedeon Richter were involved in the study design,
analysis, interpretation of data, and decision to present these results.
Antonia Periclou, Suresh Durgam, and Nika Adham acknowledge a po-
tential conflict of interest as employees of Forest Research Institute, an
Allergan affiliate. Yih Lee, Parviz Ghahramani, and Ashok Rakhit ac-
knowledge a potential conflict of interest as employees of Forest
Research Institute at the time of the study. István Laszlovszky, Béla
Kiss, and Margit Kapás acknowledge a potential conflict of interest as
employees of Gedeon Richter Plc. Ragy Girgis has received research
funding from Otsuka and Genentech. Mark Slifstein has served as a
consultant to Amgen and has received research funding from Otsuka.
Anissa Abi-Dargham has served as a consultant for Roche, Otsuka,
Forum, and Amgen and has received research support from Takeda,
Forest Laboratories, Pierre Fabre, and CHDI Foundation. Nabeel
Nabulsi had received royalty payments from the University of Texas
M.D. Anderson Cancer Center from patented work. Deepak D’Souza,
Richard Carson, and Yiyun Huang have no disclosures to report
pertaining to this work.
References
APA (2000)Diagnostic and statistical manual of mental disorders, fourth
edition, text revision. American Psychiatric Association,
Washington DC
Barnes TR (1989) A rating scale for drug-induced akathisia. Br J
Psychiatry 154:672–676
Carson R, Barker W, Liow JS (2003) Design of a motion-compensation
OSEM list-mode algorithm for resolution-recovery reconstruction
for the HRRT. In: Metzier S (ed) 2003 I.E. nuclear science sympo-
s ium ( IEEE NUCLEAR SCIENCE SYMPOSIUM -
CONFERENCE RECORD), Portland, OR, USA, pp 3281–3285
Debelle M, Faradzs-zade S, Szatmari B, Nagy K (2014) Cariprazine in
negative symptoms of schizophrenia: post hoc analyses of a fixed-
dose, placebo- and active-controlled trial. Eur Neuropsychopharmacol
24:S534
Debelle M, Németh G, Szalai E, Szatmári B, Harsányi J, Barabássy A,
Laszlovszky I (2015) Cariprazine as monotherapy for the treatment
of schizophrenia patients with predominant negative symptoms: a
double-blind, active controlled trial. Eur Neuropsychopharamcol
25:S510
First MB, Williams JBW, Spitzer RL, Gibbon M (2007) Structured clin-
ical interview for DSM-IV-TR Axis I disorders, clinical trials ver-
sion (SCID-CT). Biometrics Research, New York State Psychiatric
Institute, New York
Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D,
Singhal T, Slifstein M, Fowles K, Ding YS, Huang Y,
Laruelle M, Carson RE, Rabiner EA (2012) Affinity and selec-
tivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in
the rhesus monkey brain in vivo. Synapse 66:489–500
Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S,
Kapur S, Wilson AA (2007) Positron emission tomography quanti-
fication of [C-11]-(+)-PHNO binding in the human brain. J Cereb
Blood Flow Metab 27:857–871
Girgis R, Xu X, Miyake N, Easwaramoorthy B, Gunn R, Rabiner E, Abi-
Dargham A, Slifstein M (2011) In vivo binding of antipsychotics to
D3 and D2 receptors: a PET study in baboons with [11]-(+)-PHNO.
Neuropsychopharmacology:887–895
Girgis RR, Xu X, Gil RB, Hackett E, Ojeil N, Lieberman JA, SlifsteinM,
Abi-Dargham A (2015) Antipsychotic binding to the dopamine-3
receptor in humans: a PETstudy with [(11)C]-(+)-PHNO. Schizophr
Res 168:373–376
Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Penny B, Rusjan P,
Wilson AA, Zipursky RB, Kapur S (2009) The dopamine D2 recep-
tors in high-affinity state and D3 receptors in schizophrenia: a clin-
ical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34:
1078–1086
Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P,
BhathenaA, Palaparthy R, SaltarelliMD,Kapur S (2010) Blockade of
[11C](+)-PHNO binding in human subjects by the dopamine D3 re-
ceptor antagonist ABT-925. Int J Neuropsychopharmacol 13:273–287
Gross G, Drescher K (2012) The role of dopamine D(3) receptors in
antipsychotic activity and cognitive functions. Handb Exp
Pharmacol:167–210
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997)
Parametric imaging of ligand-receptor binding in PET using a sim-
plified reference region model. NeuroImage 6:279–2787
Gurevich EV, Joyce JN (1999) Distribution of dopamine D3 receptor
expressing neurons in the human forebrain: comparison with D2
receptor expressing neurons. Neuropsychopharmacology 20:60–80
GuyW (1976) The abnormal movement scale. ECDEU assessment man-
ual for psychopharmacology. National Institute of Mental Health,
Rockville, MD, pp. 218–222 DHEW Publication No. 76-338
3510 Psychopharmacology (2016) 233:3503–3512
Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI,
Pásztor G, Zájer-Balázs M, Kapás M, Csongor E, Domány G,
Tihanyi K, Szombathelyi Z (2011) Cariprazine (RGH-188), a potent
D3/D2 dopamine receptor partial agonist, binds to dopamine D3
receptors in vivo and shows antipsychotic-like and procognitive
effects in rodents. Neurochem Int 59:925–935
Gyertyán I, Sághy K (2004) Effects of dopamine D3 receptor antagonists
on spontaneous and agonist-reduced motor activity in NMRI mice
andWistar rats: comparative study with nafadotride, U 99194A and
SB 277011. Behav Pharmacol 15:253–262
Gyertyán I, SághyK, Laszy J, Elekes O, Kedves R, Gémesi LI, Pásztor G,
Zájer-Balázs M, Kapás M, Ágai Csongor E, Domány G, Kiss B,
Szombathelyi Z (2008) Subnanomolar dopamine D3 receptor antag-
onism coupled to moderate D2 affinity results in favourable
antipsychotic-like activity in rodent models: II. Behavioural charac-
terisation of RG-15. Naunyn Schmiedeberg’s Arch Pharmacol 378:
529–539
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN,
Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y,
Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M,
Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC,
Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE
(2007) Consensus nomenclature for in vivo imaging of reversibly
binding radioligands. J Cereb Blood Flow Metab 27:1533–1539
Kapás M, Mészáros G, Yu B, Shi J, Knoche B, Laszlovszky I,
Bolton G (2008) Comparison of the pharmacokinetic behavior
of RGH 188 in schizophrenic patients and healthy volunteers.
Eur Neuropsychopharmacol 18:S433
Keator D, Mukherjee J, Preda A, Highum D, Gage A, Potkin S (2009)
Dopamine D2 and D3 receptor occupancy of cariprazine in schizo-
phrenic patients. Schizophr Bull 35:154
Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G,
Fazekas K, Hornok K, Orosz S, Gyertyán I, Ágai-Csongor E,
Domány G, Tihanyi K, Adham N, Szombathelyi Z (2010)
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring,
D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychot-
ic candidate: in vitro and neurochemical profile. J Pharmacol Exp
Ther 333:328–340
Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E,
Bugovics G, Fazekas K, Gyertyán I, Ágai-Csongor E,
Domány G, Szombathelyi Z (2008) Subnanomolar dopamine
D3 receptor antagonism coupled to moderate D2 affinity results
in favourable antipsychotic-like activity in rodent models: I.
Neurochemica l charac te r i sa t ion of RG-15 . Naunyn
Schmiedeberg’s Arch Pharmacol 378:515–528
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for
PET receptor studies. NeuroImage 4:153–158
Laszlovszky I, Németh G,Mészáros GP, Kapás M, Brooks DJ, Pavese N,
SZombathelyi Z (2007) Dopamine D2/D3 receptor occupancy of
RGH-188, a D3/D2, antagonist/partial agonist antipsychotic, in
healthy volunteers. Eur Neuropsychopharmacol 17(Suppl 4):S455
Laszy J, Laszlovszky I, Gyertyán I (2005) Dopamine D3 receptor antag-
onists improve the learning performance in memory-impaired rats.
Psychopharmacology 179:567–575
McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN,
Wilson AA (2010) The antipsychotics olanzapine, risperidone, clo-
zapine, and haloperidol are D2-selective ex vivo but not in vitro.
Neuropsychopharmacology 35:1826–1835
Mészáros G, Kapás M, Borsos M, Laszlovszky I, Németh G, Tihanyi K,
Szombathelyi Z (2007) Pharmacokinetics of RGH 188, a novel do-
pamine D3/D2 antagonist/partial agonist atypical antipsychotic, in
healthy male volunteers. Eur Neuropsychopharmacol 17:S451
Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M
(2000) S33084, a novel, potent, selective, and competitive antago-
nist at dopamine D(3)-receptors: II. Functional and behavioral
profile compared with GR218,231 and L741,626. J Pharmacol
Exp Ther 293:1063–1073
Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D,
Cistarelli L, Billiras R, Gobert A (2007) Selective blockade of do-
pamine D(3) versus D(2) receptors enhances frontocortical cholin-
ergic transmission and social memory in rats: a parallel neurochem-
ical and behavioural analysis. J Neurochem 100:1047–1061
Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, Remington
G, Wilson AA, Kapur S (2011) Effects of antipsychotics on D3
receptors: a clinical PET study in first episode antipsychotic naive
patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res
131:63–68
Nakamura T, Kubota T, Iwakaji A, Imada M, Kapas M, Morio Y (2016)
Clinical pharmacology study of cariprazine (MP-214) in patients
with schizophrenia (12-week treatment). Drug Des Devel Ther 10:
327–338
Nyberg S, Nakashima Y, Nordstrom AL, Halldin C, Farde L (1996)
Positron emission tomography of in-vivo binding characteristics of
atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor
occupancy studies and clinical response. Br J Psychiatry Suppl 29:
40–44
Posner K, BrownGK, Stanley B, Brent DA, Yershova KV, OquendoMA,
Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011) The
Columbia-suicide severity rating scale: initial validity and internal
consistency findings from three multisite studies with adolescents
and adults. Am J Psychiatry 168:1266–1277
Potkin S, Keator D, Mukherjee J, Preda A, Highum D, Gage A, Xie J,
Ghahramani P, Laszlovszky I (2009) Dopamine D3 and D2 receptor
occupancy of cariprazine in schizophrenic patients. Eur
Neuropsychopharmacol 19:S316
Rabiner E, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R,
Diwan M, Wilson AA, McCormick P, Gentile G, Gunn RN,
Laruelle M (2009) In vivo quantification of regional dopamine-D3
receptor binding potential of (+)PHNO: studies in non-hman pri-
mates and transgenic mice. Synapse 63:782–793
Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY,
Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter
AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD,
Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G,
Thewlis KM, Trail B, Vong AK, Hagan JJ (2000) Pharmacological
actions of a novel, high-affinity, and selective human dopamineD(3)
receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:
1154–1165
Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian
A, RobiesonWZ, Wang Y, Goss SL, Greco N, Saltarelli MD (2011)
A double-blind, randomized, placebo-controlled study of the dopa-
mine D(3) receptor antagonist ABT-925 in patients with acute
schizophrenia. J Clin Psychopharmacol 31:221–225
Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P,
Costentin J, Schoenfelder A, Garrido F, Mann A, et al. (1995)
Nafadotride, a potent preferential dopamine D3 receptor antag-
onist, activates locomotion in rodents. J Pharmacol Exp Ther
275:1239–1246
Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M,
Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S,
Gunn R, Rabiner EA, Laruelle M (2010) Imaging dopamine D-3
receptors in the human brain with positron emission tomography,
[C-11]PHNO, and a selective D-3 receptor antagonist. Biol
Psychiatry 68:392–399
Seeman P (2001) Antipsychotic drugs, dopamine receptors, and schizo-
phrenia. Clin Neurosci Res 1:53–60
Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horvath A, Pasztor
G, Kapas M, Gyertyan I, Farkas S, Innis RB, Halldin C, Gulyas
B (2011) Occupancy of dopamine D(2) and D(3) and serotonin
5-HT(1)A receptors by the novel antipsychotic drug candidate,
Psychopharmacology (2016) 233:3503–3512 3511
cariprazine (RGH-188), in monkey brain measured using pos-
itron emission tomography. Psychopharmacology 218:579–587
Sigala S, Missale C, Spano P (1997) Opposite effects of dopamine D2
and D3 receptors on learning and memory in the rat. Eur J
Pharmacol 336:107–112
Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side
effects. Acta Psychiatr Scand Suppl 212:11–19
Slifstein M, Rabiner EA, Gunn RN (2012) Imaging dopamine D3 recep-
tors in vivo. In: Seeman P, Madras B, Johnson JE (eds) Imaging of
the human brain in health and disease. Neuroscience-Net
Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2011) In vitro pharma-
cology of aripiprazole, its metabolite and experimental dopamine
partial agonists at human dopamine D2 and D3 receptors. Eur J
Pharmacol 668:355–365
Toth M, Varrone A, Steiger C, Laszlovszky I, Horvath A, Kiss B,
Gyertyan I, Adham N, Halldin C, Gulyas B (2013) Brain up-
take and distribution of the dopamine D3 /D2 receptor partial
agonist [11 C]cariprazine: an in vivo positron emission tomog-
raphy study in nonhuman primates. Synapse 67:258–264
Waters N, Lofberg L, Haadsma-Svensson S, Svensson K, Sonesson C,
Carlsson A (1994) Differential effects of dopamine D2 and D3
receptor antagonists in regard to dopamine release, in vivo receptor
displacement and behaviour. J Neural Transm Gen Sect 98:39–55
Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A
(1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory
on rat locomotor activity. J Neural Transm Gen Sect 94:11–19
Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson
AA (2006) High-affinity states of human brain dopamine D2/3 re-
ceptors imaged by the agonist [C-11]-(+)-PHNO. Biol Psychiatry
59:389–394
Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D,
Houle S, Seeman P, Ginovart N (2005) Radiosynthesis and evaluation
of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-
b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of
the dopamine D2 high-affinity state with positron emission tomogra-
phy. J Med Chem 48:4153–4160
Zimnisky R, ChangG, Gyertyan I, Kiss B, AdhamN, Schmauss C (2013)
Cariprazine, a dopamine D(3)-receptor-preferring partial agonist,
blocks phencyclidine-induced impairments of working memory, at-
tention set-shifting, and recognition memory in the mouse.
Psychopharmacology 226:91–100
3512 Psychopharmacology (2016) 233:3503–3512
